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Acute renal failure research has been hampered by the lack of useful physiologic surrogate endpoints. Acute renal failure prevention and therapy studies using variables such as urine output and serum and urine chemistries have not yielded interventions proven to decrease the morbidity and mortality associated with acute renal dysfunction. Of those interventions that have been successful in smaller, phase II-level efficacy studies, none subsequently decreased the incidence of clinical (effectiveness) endpoints such as dialysis requirement or mortality in larger phase III trials. Suitable physiologic endpoints are needed to test the efficacy of new proposed therapies for the prevention and management of acute renal failure. Candidate endpoints for efficacy studies in acute renal failure prevention and management include glomerular filtration rate markers, renal blood flow, urine markers, and urine output. Possible endpoints for efficacy studies of renal replacement therapy in acute renal failure include serum markers of renal function and a variety of nonrenal markers. In this article, we present an approach to the choice of physiologic endpoints to determine the efficacy of interventions in acute renal failure. The lack of significant progress in the prevention and management of acute renal failure (ARF) has been commonly attributed, in part, to the failure to identify suitable physiologic surrogate endpoints for use in research studies testing the efficacy of new interventions. For example, the standardized use of serum cardiac enzyme concentrations and electrocardiographic criteria has facilitated rapid progress in the management of coronary insufficiency, markedly decreasing the morbidity and mortality of acute myocardial infarction. By contrast, ARF prevention and therapy studies using variables such as urine output and serum and urine chemistries have not yielded interventions proven to decrease the morbidity (including requirement for dialysis) and mortality associated with acute renal dysfunction. In fact, very few ARF studies have even demonstrated a beneficial effect on the most commonly used physiologic surrogate endpoints, the serum urea nitrogen and creatinine concentrations [1,2]. Of those interventions that have been successful in smaller, phase II-level efficacy studies, most prominently exemplified by the experiences with atrial natriuretic peptide [3] and insulin-like growth factor [4], none subsequently decreased the incidence of clinical (effectiveness) endpoints such as dialysis requirement or mortality in larger phase III trials [5] [6] [7] . Clearly, it must be determined which physiologic endpoints should be used to test the efficacy of new proposed therapies for the prevention and management of ARF. Candidate endpoints for efficacy studies in ARF prevention and management include glomerular filtration rate (GFR) markers, renal blood flow, urine markers, and urine output. Possible endpoints for efficacy studies of renal replacement therapy (RRT) in ARF include serum markers of renal function and a variety of nonrenal markers.
Glomerular filtration rate markers
Because there are no pharmacotherapies that have been proven to alter clinical endpoints (dialysis, mortality) in patients with ARF, it cannot be discerned definitively what changes in currently available serum GFR markers (urea, creatinine) are predictive in smaller phase II studies of success in subsequent phase III trials with clinical endpoints. In other words, although some interventions were shown have efficacy in altering physiologic endpoints (eg, prevention of serum creatinine increments after radiocontrast administration in high-risk patients) [1,2], none have been validated by a study of sufficient size to detect effectiveness in altering major clinical end-points such as dialysis and mortality. Of course, there are abundant data suggesting that patients with severe ARF have adverse outcomes, so it follows that advanced azotemia and severe oliguria are at some level indisputable adverse prognostic markers [8] . Admittedly, alterations in urea and creatinine levels in the course of phase II studies may be caused by numerous factors other than changes in GFR (eg, volume status, catabolism, hemorrhage, corticosteroids, rhabdomyolysis, drugs) and are insensitive compared with more sophisticated clearance measurements of GFR. Nevertheless, the currently available GFR markers do satisfy a number of the specific, measurable, achievable, realistic, time-related (SMART) criteria commonly used to evaluate the outcome or objective of an intervention [9] . Table 1 presents an analysis of the utility of currently available physiologic markers of renal function to monitor the effects of a therapeutic intervention aimed at the prevention or management of ARF [7,10-14].
Studies validating the prognostic value of efficacy in achieving alterations in these or other biochemical GFR markers in predicting effectiveness in improving clinical outcomes are needed. Such studies should use the same markers selected to define ARF [15] . Sample size should be estimated based on variability in the primary biochemical endpoint in the study population from either a preliminary study or a literature review. Studies should be designed to have 90% power to detect a betweengroup difference of one SD or less, with ␣ error less than 
Renal blood flow
Although decreased renal perfusion is a recognized model of renal injury in animals, it has not been documented to be of etiologic significance in the development of ARF in humans. It is thus unclear whether decreased renal perfusion is a relevant physiologic endpoint for efficacy studies in ARF. Clearly, systemic hypotension is a common precursor of ARF in humans, but other documented etiologic factors, including ischemiareperfusion, circulating nephrotoxins (eg, drug toxicity, cytokines, pigments), acidosis, and hypoxemia coexist. However, vasoactive therapies have been used in the management of acutely ill patients and may also alter renal blood flow. Importantly, the logic for defending organ perfusion pressure with vasoactive agents presumes both pressure-dependent renal flow and flowdependent renal function. Clinical trials of patients in septic shock have demonstrated that renal function and urine output increase once mean arterial pressure is increased above 60 mm Hg by the use of vasopressor therapy [20,21,22•]. Whether this benefit is caused by increased global renal blood flow, alterations in renal blood flow distribution, or some other pressuredependent mechanism is unclear.
Of the available techniques to assess renal perfusion, para-amino hippuric acid clearance is not a valid method to assess renal plasma flow because renal para-amino hippuric acid extraction is impaired in critical illness, cardiac surgery, postrenal transplantation, and ARF [13, 14] . Primary methods to assess renal blood flow include angiography, indicator extraction or dilution via a renal vein catheterization (para-amino hippuric acid and thermodilution) [23], and ultrasonography [12, 24] . Radiocontrast nephropathy is probably the most studied form of human ARF. The pathogenesis is thought to involve both ischemia (renal vasoconstriction) and dye-nephrotoxicity. However, when global renal blood flow was measured during radiocontrast administration, it was not diminished [25] . In animal models, whereas cortical blood flow increases after radiocontrast administration, medullary blood flow is diminished [26, 27] . Thus, intrarenal blood flow distribution may be altered in humans receiving radiocontrast, but this possibility has not been studied to date. Blood oxygen level-dependent magnetic resonance imaging has been used to measure intrarenal blood flow redistribution in humans [28], but it is impractical for use in many patients developing ARF. Other poten- tial techniques include microbubble contrast ultrasonography [29] . We suggest that these techniques be used to assess renal hemodynamic profiles in human ARF, particularly in studies using vasoactive agents (putative renal vasodilators, vasopressors) to prevent or treat ARF.
Urine markers
Although some data suggest the utility of urinary electrolyte or other chemistries in the differential diagnosis of ARF [30•], none of these methods has proven reliable in clinical practice [31] . Similarly, none has been conclusively demonstrated to be useful in following the course of ARF or in predicting outcome [32, 33] . Nevertheless, because of the sound physiologic rationale underlying the assessment of renal tubular function with these substances, we recommend their inclusion in phase II protocols studying the effects of new interventions on renal function in patients at risk for or developing ARF.
Microscopic urinalysis of the urinary sediment, which is commonly used to assess patients with ARF, is often qualitatively useful in the differential diagnosis of renal insufficiency and can disclose some pathognomic findings (eg, erythrocyte casts signaling glomerulonephritis; leukocyte casts with infectious, allergic, or immune interstitial nephritis) [34] . However, the reproducibility and predictive value of urinalysis in the differential diagnosis and monitoring of ARF have not been determined. We recommend that a skilled microscopic analysis of the urinary sediment be performed at entry and possibly serially in ARF studies to assess potential utility as a diagnostic marker or index of therapeutic effect.
Emerging data suggest that urinary concentrations of tubular proteins may provide a more sensitive index of renal tubular injury than urine electrolytes, but the clinical relevance of these markers has not been determined at this point [35] . Similarly, although proteomics may yield urinary biomarkers of greater sensitivity to detect and monitor acute renal injury, none are available for clinical or widespread research use at this time [36, 37] .
Urine output
The traditional definition of oliguria used in the ARF literature is less than 400 mL/24 h. This is the minimum urine volume required to excrete the daily metabolic solute load in a healthy adult, assuming maximum urine-concentrating ability; therefore, oliguria below this cutoff value signals inadequate GFR and acute renal insufficiency [38] . Of course, the daily metabolic solute load in a catabolic critically ill patient far exceeds that in healthy subjects, and ICU patients developing renal insufficiency lose the ability to concentrate urine maximally [39] . Furthermore, this urine volume (400 mL/d) is inadequate to prevent positive fluid balance in the vast majority of critically ill patients, who routinely have obligate fluid intakes of liters. These and other data suggest that the definition of adequate urine output versus oliguria should be reinterpreted.
To facilitate clinical studies and management, it is important to define nominal ranges of renal function (normal vs grades of abnormality) from measured physiologic variables. As a general principle, the defined ranges for measured markers of renal function and response to therapy should be based on objective criteria that include measures of related severity of illness, physiologic correlates with measured variable, and direct results of derangements in these variables and subsequent outcome (when available). For example, an approach to assessing the impact of specific markers used in the definition of ARF is to ascertain their effect on outcome from large patient data sets, such as the logistic regression data in Table 2 . Data from ICU outcome studies show an adverse prognostic significance of oliguria, not only with the traditional 400 mL definition but also with higher urine outputs to 750 mL/d (30 mL/h). Specifically, data from the Logistic Organ Dysfunction ICU outcome study of 13,000 patients from Europe and North America showed an adverse prognostic significance of oliguria both with a traditional definition (<500 mL/d) and with higher urine outputs (<750 mL/d, 30 mL/h) [40••]. As shown in Table 2 , this study also reported that increases in serum creatinine well below most clinical thresholds for initiating RRT are associated with increased mortality. Another international study of 6400 patients found that transient urine output decrements defined by the higher range (<30 mL/h) that was significant in the Logistic Organ Dysfunction study were predictive of renal insufficiency [41] . Together, these data suggest that urine output decrements well above the traditional 400 mL/d are associated with increased mortality. Therefore, it is recommended that investigators monitor urine output hourly in patients at risk for renal failure and that a higher than customary definition of inadequate urine output (<30 mL/h rather than 400 mL/d) be used to define oliguria.
The monitoring of urine output should be coupled with fluid balance. Simple correction of low urine output by fluid administration may result in the development of a positive fluid balance and also reverse prerenal azotemia. However, a persistently positive fluid balance over several days is associated with a poor prognosis [42] . Although poor prognosis is probably related more to the underlying disease process than to fluid resuscitation, the relation is unclear.
Although there is evidence that failure to respond to diuretics (ie, persistent severe oliguria) portends a poor renal prognosis and survival, it is not known whether this reflects the adverse effects of severe underlying renal (and systemic) tissue injury in the persistently oliguric groups or any beneficial effect of increasing urine flow in ARF. However, nonoliguric renal failure has repeatedly been shown to have a survival benefit [8]. The mechanisms underlying this benefit are not known. Potential contributory factors include less severe injury, avoidance of volume overload, minimization of hyperkalemia, ability to give intravenous fluids and nutrition, and avoidance of RRT. In any case, because fluid balance is a central aspect of normal renal function, it is important to record fluid management, diuretic therapy, and fluid balance in any clinical study of ARF. These parameters have not routinely been rigorously recorded in past ARF studies.
Markers of renal replacement therapy efficacy in acute renal failure
The required dialysis dose in ARF may be higher than with other conditions because of alterations in the peripheral circulation, solute and water exchange among tissue and body compartments, and altered metabolism in this population. The concept of a higher dose of RRT in patients with ARF contrasting with patients with endstage renal disease appears valid for a variety of reasons; for example, the distribution volume for urea is increased in ARF [43] and is increased further in ARF associated with systemic inflammation. [59] [60] [61] . Leukocyte hyporesponsiveness ex vivo is associated with profound immune dysregulation with reduced surface molecule expression (HLA class II) and inability to respond to infectious stimuli. Recovery from systemic inflammatory response syndrome is paralleled by recovery of the normal leukocyte responsiveness to proinflammatory stimuli and normal hemodynamics. Although many studies have looked at purified cell populations, the most practical approach seems to be the use of whole blood cytokine assay, because it measures cytokine production in the presence of a wide range of modulating factors (eg, soluble receptors, natural inhibitors, proteases, and so forth). Leukocyte priming is defined as the enhanced response to a second stimulus. Priming activity is important in polymorphonuclear leukocyte-mediated antimicrobial action and in the pathogenesis of tissue damage. Several investigators have reported the priming of polymorphonuclear leukocytes in septic and injured patients [59] [60] [61] . Priming mediators such as IL-8 act on circulating polymorphonuclear leukocytes by stimulating the oxidative burst; by exerting a priming effect to a secondary stimulus, such as bacterial N-formyl peptides; or both. Experimental and clinical evidence support a two-hit model for the development of multiorgan dysfunction syndrome [62, 63] , and leukocyte priming may be important in the pathogenesis of this phenomenon. The priming activity of polymorphonuclear leukocytes as detected by chemiluminescence is reduced by ultrafiltration and is mediated, at least in part, by ultrafiltered IL-8 [64] .
Finally, markers of apoptosis (programmed cell death) may be appropriate nonrenal endpoints for RRT efficacy studies in ARF. Apoptosis has been related to membrane biocompatibility, pre-T-cell activation, and CD14 expression in the end-stage renal disease population [65] [66] [67] . Apoptosis of monocytes has also been found to cor-relate with the severity of predialysis chronic renal insufficiency [65] . In critically ill patients, accelerated apoptosis is a marker of severity of the septic process. Inhibitors of caspases, regulatory proteins involved in the signal transduction of apoptogenic stimuli, improve survival in sepsis. Furthermore, caspase inhibition prevents cardiac dysfunction and myocardial apoptosis in a rat model of sepsis. Sepsis-associated mediators (hormones, neuropeptides, proinflammatory and anti-inflammatory cytokines, reactive oxygen species) are usually either proapoptogenic or antiapoptogenic. It is presumed that the cellular environment generated during systemic inflammatory response syndrome/multiple organ dysfunction syndrome favors apoptosis rather than survival. Based on such data, it seems rational to study markers of apoptosis as markers of RRT efficacy in critically ill patients with ARF. Suitable approaches might include assays of the expression of the apoptotic receptor Fas and of its ligand to study the upregulation of apoptotic constituents in peripheral blood mononuclear cells [68, 69] .
Conclusions
We find that the literature on ARF prevention and management has generally lacked the rigorous approach necessary to identify effective therapies successfully. Furthermore, we believe that the use of reliable physiologic endpoints for efficacy studies, which are proven to predict clinical effectiveness, will focus therapeutic trials in high-yield areas. We hope that standardization of this approach will lead to rapid advances in ARF therapy. 
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